Modulatory effects of 17?-estradiol on acute lung inflammation after total occlusion of the descending aorta in male rats

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorANUNCIACAO, Lucas Ferreira da
dc.contributor.authorSOUSA, Marcelo Nunes de
dc.contributor.authorVIDAL-DOS-SANTOS, Marina
dc.contributor.authorARMSTRONG-JR, Roberto
dc.contributor.authorMOREIRA, Luiz Felipe Pinho
dc.contributor.authorCORREIA, Cristiano Jesus
dc.contributor.authorBREITHAUPT-FALOPPA, Ana Cristina
dc.date.accessioned2022-12-21T13:19:15Z
dc.date.available2022-12-21T13:19:15Z
dc.date.issued2022
dc.description.abstractAs a consequence of systemic inflammation caused by ischemia and reperfusion (I/R) due to aortic occlusion, the lungs can exhibit increased microvascular permeability, local release of pro-inflammatory mediators, and leukocyte infiltration. Lung tissue infiltration by activated neutrophils is followed by acute respiratory distress syndrome, which is linked to acute pulmonary microvascular damage, high mortality rates, and organ dysfunction. Previous studies have demonstrated that female sex hormones modulate the inflammatory response and that prophylactic treatment with 178-estradiol (E2) can prevent fatalities and preserve mesenteric perfusion and intestinal integrity after ischemia/reperfusion induced by aortic occlusion. In this study, we focused on the protective effects of estradiol after aortic ischemia/reperfusion by evaluating lung injury and endothelial al-terations. Upon anesthesia and mechanical ventilation, male rats were subjected to aortic occlusion for 20 min, followed by 2 h of reperfusion. In parallel, one group of rats received a single injection of estradiol (280 mu g/kg, i. v.) 30 min before ischemia. We observed increased serum concentrations of IL-18, IL-6 and IL-10 in the I/R rats and E2 was able to reduce them. E2 effects after 2 h of reperfusion resulted mainly in decreasing of edema, iNOS expression and preventing leukocyte infiltration. Overall, our data indicate that estradiol might be a supple-mentary approach to deal with systemic processes and lung deterioration.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipFundacao de Amparo Pesquisa do Estado de Sao Paulo [FAPESP] [2020/11211-6, 2021/07455-0]
dc.description.sponsorship[2018/25759-3]
dc.identifier.citationINTERNATIONAL IMMUNOPHARMACOLOGY, v.113, article ID 109311, 9p, 2022
dc.identifier.doi10.1016/j.intimp.2022.109311
dc.identifier.eissn1878-1705
dc.identifier.issn1567-5769
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50447
dc.language.isoeng
dc.publisherELSEVIEReng
dc.relation.ispartofInternational Immunopharmacology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright ELSEVIEReng
dc.subjectIschemia and Reperfusioneng
dc.subject17&betaeng
dc.subject-estradioleng
dc.subjectLung inflammationeng
dc.subjectiNOSeng
dc.subject.othernitric-oxideeng
dc.subject.otherintestinal ischemiaeng
dc.subject.otherpulmonary-edemaeng
dc.subject.otherestradioleng
dc.subject.other17-beta-estradioleng
dc.subject.otherpathogenesiseng
dc.subject.otherinjuryeng
dc.subject.othermodeleng
dc.subject.wosImmunologyeng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleModulatory effects of 17?-estradiol on acute lung inflammation after total occlusion of the descending aorta in male ratseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus5
hcfmusp.contributor.author-fmusphcLUCAS FERREIRA DA ANUNCIACAO
hcfmusp.contributor.author-fmusphcMARCELO NUNES DE SOUSA
hcfmusp.contributor.author-fmusphcMARINA VIDAL DOS SANTOS
hcfmusp.contributor.author-fmusphcROBERTO ARMSTRONG JUNIOR
hcfmusp.contributor.author-fmusphcLUIZ FELIPE PINHO MOREIRA
hcfmusp.contributor.author-fmusphcCRISTIANO DE JESUS CORREIA
hcfmusp.contributor.author-fmusphcANA CRISTINA BREITHAUPT FALOPPA
hcfmusp.description.articlenumber109311
hcfmusp.description.volume113
hcfmusp.origemWOS
hcfmusp.origem.pubmed36252489
hcfmusp.origem.scopus2-s2.0-85140274676
hcfmusp.origem.wosWOS:000878199000001
hcfmusp.publisher.cityAMSTERDAMeng
hcfmusp.publisher.countryNETHERLANDSeng
hcfmusp.relation.referenceBarocelli E, 2006, NITRIC OXIDE-BIOL CH, V14, P212, DOI 10.1016/j.niox.2005.11.006eng
hcfmusp.relation.referenceBoateng S, 2013, DM-DIS MON, V59, P83, DOI 10.1016/j.disamonth.2012.12.004eng
hcfmusp.relation.referenceBooth EA, 2008, CARDIOVASC TOXICOL, V8, P101, DOI 10.1007/s12012-008-9022-2eng
hcfmusp.relation.referenceBouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008eng
hcfmusp.relation.referenceBown MJ, 2001, EUR J VASC ENDOVASC, V22, P485, DOI 10.1053/ejvs.2001.1522eng
hcfmusp.relation.referenceBreithaupt-Faloppa AC, 2014, SHOCK, V41, P208, DOI 10.1097/SHK.0000000000000092eng
hcfmusp.relation.referenceCavalcante LP, 2018, INTERACT CARDIOV TH, V26, P196, DOI 10.1093/icvts/ivx314eng
hcfmusp.relation.referenceCavriani G, 2004, EUR J PHARMACOL, V494, P241, DOI 10.1016/j.ejphar.2004.04.048eng
hcfmusp.relation.referenceCuzzocrea S, 2000, ENDOCRINOLOGY, V141, P1455, DOI 10.1210/en.141.4.1455eng
hcfmusp.relation.referenceCuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014eng
hcfmusp.relation.referenceDubey RK, 2001, HYPERTENSION, V37, P640, DOI 10.1161/01.HYP.37.2.640eng
hcfmusp.relation.referenceEltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025eng
hcfmusp.relation.referenceFantozzi ET, 2018, J SURG RES, V221, P1, DOI 10.1016/j.jss.2017.07.038eng
hcfmusp.relation.referenceHuertas A, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00745-2017eng
hcfmusp.relation.referenceIglesias JL, 1998, J SURG RES, V80, P156, DOI 10.1006/jsre.1998.5435eng
hcfmusp.relation.referenceKlein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90eng
hcfmusp.relation.referenceKowalczyk A, 2015, ARCH IMMUNOL THER EX, V63, P41, DOI 10.1007/s00005-014-0310-1eng
hcfmusp.relation.referenceManiatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009eng
hcfmusp.relation.referenceMiller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7eng
hcfmusp.relation.referenceMoris DN, 2014, INT J CLIN EXP MED, V7, P2402eng
hcfmusp.relation.referencePeng XQ, 2005, AM J RESP CRIT CARE, V172, P470, DOI 10.1164/rccm.200411-1547OCeng
hcfmusp.relation.referencePerl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]eng
hcfmusp.relation.referencede Sousa PTR, 2018, J VASC SURG, V67, P597, DOI 10.1016/j.jvs.2016.12.125eng
hcfmusp.relation.referenceSobral MLP, 2022, EUR J CARDIO-THORAC, V61, P666, DOI 10.1093/ejcts/ezab381eng
hcfmusp.relation.referenceVillar J, 2011, CURR OPIN CRIT CARE, V17, P13, DOI 10.1097/MCC.0b013e32834271fbeng
hcfmusp.relation.referenceZemans RL, 2004, CRIT CARE, V8, P469, DOI 10.1186/cc2906eng
hcfmusp.relation.referenceZhang ML, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/9921897eng
hcfmusp.relation.referenceZhang P, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105787eng
hcfmusp.relation.referenceZhu TB, 2016, CELL PHYSIOL BIOCHEM, V38, P1575, DOI 10.1159/000443098eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationc75c2685-215a-4b8b-9cbf-734523f608ea
relation.isAuthorOfPublication46c0ad9a-7fb1-4068-9d67-53bf8a58e60e
relation.isAuthorOfPublication686fb6bc-5f69-41e1-be4b-20fe936d074e
relation.isAuthorOfPublicationa1c98670-cafd-4296-8e62-23e17cc3ae82
relation.isAuthorOfPublication82d80256-8c59-4d50-813e-702ac179713d
relation.isAuthorOfPublicationfd6721b6-3a47-404f-a2ff-5b6770f85c3d
relation.isAuthorOfPublicationc30b994d-83bd-4dd2-9640-3577754e17a0
relation.isAuthorOfPublication.latestForDiscoveryc75c2685-215a-4b8b-9cbf-734523f608ea
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_ANUNCIACAO_Modulatory_effects_of_17estradiol_on_acute_lung_inflammation_2022.PDF
Tamanho:
4.82 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)